Summit Wealth Group LLC Co. Purchases 37,996 Shares of Novo Nordisk A/S $NVO

Key Points

• Summit Wealth Group opened a new Novo Nordisk position, buying 37,996 shares in the third quarter, valued at approximately $1.44 million.
• Hedge funds and other institutional investors own 11.54% of Novo Nordisk; several other firms also reported new stakes during recent quarters.
• Analyst sentiment is mostly cautious: the consensus rating is Hold, based on five Buy, 16 Hold, and five Sell ratings, with an average price target of $59.44.

Summit Wealth Group LLC Co. purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 37,996 shares of the company's stock, valued at approximately $1,440,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Scarborough Advisors LLC bought a new position in Novo Nordisk A/S in the 1st quarter worth $26,000. Root Financial Partners LLC purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $32,000. Continuum Advisory LLC bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $38,000. Latitude Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $38,000. Finally, Markowski Investments bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $43,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Cfra cut shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating and set a $38.00 price target on the stock. in a research report on Tuesday, September 22nd. Jefferies Financial Group restated a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. DZ Bank reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. BMO Capital Markets set a $40.00 price objective on Novo Nordisk A/S and gave the company a "market perform" rating in a research report on Monday, October 12th. Finally, Weiss Ratings downgraded Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, October 8th. Five analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $59.44.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo plans to repurchase 41.7 million shares under its $15 billion buyback program, which may support demand for the stock. Novo Nordisk stock and repurchases
• Positive Sentiment: New Wegovy and investigational CagriSema findings are expected at ObesityWeek, including real-world Wegovy results and additional CagriSema weight-loss outcomes. Strong data could bolster the obesity-drug pipeline and help restore confidence in future growth. Novo Nordisk obesity data
• Positive Sentiment: A valuation-focused article highlights NVO’s discount to sector peers, while another identifies the company as a potentially attractive dividend stock after a difficult year. These views may appeal to value-oriented investors, though they do not resolve near-term business risks. Novo Nordisk valuation Dividend-stock article
• Neutral Sentiment: Q3 results are a key upcoming catalyst. Investors are watching GLP-1 sales and management’s outlook; an article’s reference to substantial upside based on GF Value is a valuation estimate, not a forecast of earnings or share performance. Q3 results preview Earnings watch
• Negative Sentiment: Pre-earnings coverage flags intensifying GLP-1 competition, earnings estimate cuts and pricing pressure. Another report frames the November outlook around a trimmed target, while commentary points to a legal setback, Eli Lilly’s higher competitive bar and caveats around CagriSema. These concerns could weigh on growth expectations. Pre-earnings risks November challenges

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $40.14 on Wednesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $179.23 billion, a P/E ratio of 9.81, a P/E/G ratio of 1.37 and a beta of 0.70. The business's 50 day moving average price is $40.97 and its 200-day moving average price is $44.15. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The company had revenue of $11.98 billion during the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.